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Testicular germ cell tumour (GCT) is not an AIDS-defining illness despite an increased incidence in men with HIV infection. We
performed a matched case-control study comparing outcomes in HIV-positive men and the general population with GCT, using three
age and stage matched controls for each case. There was no difference in the 5-year GCT-free survival between cases and controls.
However, overall survival was significantly decreased in the cases (log rank P¼0.03). HIV was responsible for 70% of this mortality.
The relapse-free survival for stage I patients treated with orchidectomy and surveillance was not affected by HIV status (log rank
P¼0.68). There was no difference in disease free survival in patients with metastatic disease (log rank P¼0.78). The overall survival
has not improved since the introduction of highly active antiretroviral therapy (log rank P¼0.4). Thus, HIV-related GCT is not more
aggressive than GCT in the general population.
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Although non-Hodgkin’s lymphoma (NHL) and Kaposi’s sarcoma
account for the vast majority of HIV-1-associated malignancies,
other tumours, such as germ cell tumours (GCT), also occur more
frequently in HIV-1 infection (Logothetis et al, 1985; Gabutti et al,
1995; Goedert et al, 1998; Lyter et al, 1995; Dal Maso et al, 2001;
Frisch et al, 2001). These non-AIDS-defining tumours are
relatively rare, and published series have been small. Therefore,
accurately assessing the outcome of these patients and the
influence of HIV on the course of GCT have been difficult
(Damstrup et al, 1989; Moyle et al, 1991; Bernardi et al, 1995;
Timmerman et al, 1995; Hentrich et al, 1996; Fizazi et al, 2001).
Our group recently reported a large series of HIV-1-related GCT
(Powles et al, 2003a). It showed that these tumours occur more
frequently in HIV-1, and that highly active antiretroviral therapy
(HAART) has not resulted in a major change in the incidence of
the disease. Moreover, patients had a good outcome with respect to
the GCT, and the majority of the mortality in this cohort related to
HIV-1 infection.
Unfortunately, like other previously published series, our study
did not directly compare HIV-positive and -negative individuals,
and therefore uncertainty surrounding the relative outcome of
these patients remains. This is especially true in three subgroups of
patients with HIV-related GCT.
The first group of patients are those with stage I HIV-related
GCT who are treated with orchidectomy and surveillance alone. It
has been found that tumour infiltrating lymphocytes may improve
the prognosis in stage I GCT managed by surveillance (Nakanoma
et al, 1992; Parker et al, 2002). Hence, it is postulated that HIV
patients may be at increased risk of relapse of disease due to lack
of immune surveillance, and it is currently not known if their
outcome is the same as HIV-negative men.
The second area of uncertainty relates to HIV-positive patients
with metastatic GCT. There is some speculation that patients with
HIV-1 have increased intrinsic resistance to chemotherapy, despite
HAART and similar treatment regimens. These data come from
patients with HIV-related NHL, and is thought to involve high
levels of expression of the multidrug-resistant gene (MDR-1) that
encodes the p-glycoprotein efflux pump (Little et al, 2000; Tulpule
et al, 2002). Currently, there is no data comparing the outcome of
HIV-positive and -negative patients with metastatic GCT.
The final area of ambiguity relates to the impact of HAART on
the survival of patients with GCT. It appears that HAART has a
beneficial effect on the outcome of HIV patients with other
malignancies (Bower et al, 1999; Ribera et al, 2002; Tam et al, 2002;
Gerard et al, 2003; Powles et al, 2003b); however, this has not been
shown in patients with GCT.
Therefore, in this study, we compared the treatment outcomes
for HIV-positive and -negative men with GCT, with particular
emphasis on patients with stage I disease treated with orchidect-
omy and surveillance, as well as the survival of patients with
metastatic disease. We also examined the effects of HAART on the
response to chemotherapy and overall survival.
PATIENTS AND METHODS
The clinical details of patients with HIV-related GCT, diagnosed
since the beginning of the HIV epidemic in 1983, were retrieved
from prospective data bases from six HIV centres Chelsea and
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lWestminster Hospital (London, UK), Rigshospitalet Hospital
(Copenhagen, Denmark), St Bartholomew’s and Royal London
Hospital (London), Royal Free Hospital (London), Royal Sussex
County Hospital (Brighton) and Guys and St Thomas’ Hospital
(London). The HIV-negative control group was derived from a
large prospective cohort from one treatment centre (St Bartholo-
mew’s and Royal London Hospital), and only men diagnosed after
1983 were selected.
For each HIV-positive case patient, three HIV-negative controls
were identified who were matched for stage, histology, age (within
5 years of the case patient) and date of diagnosis (within 5 years of
the case patient). Patients diagnosed prior to 1 January 1996 were
defined as being in the pre-HAART era, while those diagnosed
after this date were ascribed to the post-HAART era.
All patients had histologically confirmed GCT. Staging was
classified using the American Joint Committee on Cancer staging
system (AJCC, 1997). Patients with metastatic disease were also
classified using the International Germ Cell Cancer Collaboration
Group (IGCCCG) prognostic scoring scheme, which divides
metastatic GCT into good, intermediate and poor prognosis
groups (IGCCCG, 1997). Response to treatment and toxicity was
evaluated using the RECIST guidelines and the National Cancer
Institute common toxicity criteria (CTC) respectively (Therasse
et al, 2000). Disease-free survival and overall survival were plotted
according to the Kaplan–Meier method (Kaplan and Meier, 1958).
RESULTS
In all, 35 were with HIV-related GCT were identified and matched
with 105 HIV-negative controls. The patient characteristics are
described in Table 1. The overall survival of the HIV-positive
cohort was significantly decreased when compared to the HIV-
negative group (log rank P¼0.0077). The 2- and 5-year actuarial
survivals are 94% (95% CI: 86–100) and 76% (95% CI: 60–2) for
the HIV-positive patients compared to 94% (95% CI: 90–98) and
90% (95% CI: 84–96) for the HIV-negative group. However, there
is no difference in the disease-free survival between the two groups
(log rank P¼0.8). The 2- and 5-year actuarial disease-free
survivals are 82% (95% CI: 69–95) and 82% (95% CI: 69–95)
for the HIV-positive patients compared to 82% (95% CI: 74–90)
and 80% (95% CI: 72–88) for the HIV-negative group, see Table 1,
Figures 1 and 2.
Effect of HAART on survival
In total, 21 patients were diagnosed with GCT before the
introduction of HAART in 1996 and 14 were diagnosed after this
date. Patients in the pre-HAART era had a worse overall survival
than the control population (log rank P¼0.03, see Figure 3). The
2- and 5-year actuarial survivals are 91% (95% CI: 79–100) and
73% (95% CI: 54–92) for the HIV-positive patients in the pre-
HAART era. However, since the introduction of HAART, the
outcome has improved due to a decrease in HIV-related deaths
(seven in the pre-HAART era and none in the post-HAART era,
Table 1 Characteristics and outcome of patients with GCT
HIV +ve HIV  ve
Number 35 105
Median age (range) 34 years (27–64) 33 years (25–64 years)
Number with seminoma 26 (74%) 78 (74%)
Number with metastatic disease 14 (40%) 42 (40%)
Median follow-up (range) 4.6 years (0.3–14) 4.3 years (0.1–17.2)
GCT-related deaths 3 (9%) 11(10% )
Other deaths (including HIV)* 7 (20%) 0
*Po0.01. GCT¼germ cell tumour.
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Figure 1 Kaplan–Meier overall survival duration curve from diagnosis of
GCT for patients with HIV infection and matched controls.
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Figure 2 Kaplan–Meier germ cell cancer-free survival duration curve
from diagnosis of GCT for patients with HIV infection and matched
controls.
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Figure 3 Kaplan–Meier overall survival duration curve from diagnosis of
GCT for patients with HIV infection comparing patients who presented in
the pre- and the post-HAART eras.
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the pre- and post-HAART eras (2 and 1, respectively, P¼0.7). The
2- and 5-year actuarial survivals are 100 and 88% (95% CI: 66–
100) for the HIV-positive patients in the post-HAART era.
Patients with metastatic disease
In all, 14 patients presented with metastatic disease and their
characteristics are described in Table 2. All but one were treated
with curative intent, using standard platinum-based combination
chemotherapy, see Table 3. The remaining patient had advanced
HIV disease in the pre-HAART era and declined treatment. Two
(15%) patients required a dose reduction (one due to myelosup-
pression and one because of nephrotoxicity). Two (15%) other
patients suffered grade 3–4 myelosuppression and two (15%)
developed grade 3–4 neurotoxicity. The toxicity details are not
available for the HIV-negative cohort and therefore cannot be
compared directly. The GCT-free survival of the HIV-positive and
-negative groups was not significantly different (log rank P¼0.78)
see Table 2 and Figure 4. The 2- year disease-free survivals for
patients with metastatic GCT are 77% (95% CI: 55–99) for those
who are HIV seropositive and 80% (95% CI: 68–92) for those who
are HIV seronegative.
Stage I patients managed with orchidectomy and
surveillance
Of the 21 (81%) HIV-positive patients with stage I GCT, 17 were
treated with orchidectomy and surveillance alone. The details of
these patients are shown in Table 4. The GCT relapse-free survival
of this group was not different to that of the matched HIV-negative
population (log rank P¼0.91) see Table 4 and Figure 5. The 2-year
disease-free survivals for patients with stage I disease managed by
orchidectomy and surveillance are 81% (95% CI: 63–100) for HIV-
positive men and 79% (95% CI: 67–91) for HIV-negative men.
Other patients with stage I HIV-related GCT
The remaining five patients with stage I disease were treated with
orchidectomy and adjuvant radiotherapy (4) or chemotherapy (1).
Once again, standard regimens designed for HIV negatives were
used. None of these patients have relapsed or died from GCT-
related disease.
Table 2 Characteristics and outcome of patients with metastatic GCT
HIV +ve HIV –ve
Number 14 42
Median age (range) 36 years (27–44 years) 31 years (21–53 years)
Median follow-up (range) 4.6 years (0.3–9 years) 4.3 years (0.1–13.2 years )
IGCCCG prognostic classification
Good 8 (57%) 27 (57%)
Medium 5 (36%) 15 (36%)
Poor 1 (7%) 5 (7%)
GCT-related deaths 2 (14% ) 9 (21% )
HIV-related deaths 2 (14% ) 0
GCT¼germ cell tumour; IGCCCG-International Germ Cell Cancer Collaboration
Group.
Table 3 Treatment details for patients with metastatic HIV-related GCT
Regimen Number of patients
BEP X3 5
BEP X4 3
BEP X5 1
EP X4 3
Radiotherapy (40Gy in 20#) 1
BEP¼bleomycin, etoposide and cisplatin in 3 weekly cycles; EP¼Etoposide and
cisplatin in 3 weekly cycles; GCT¼germ cell tumours.
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Figure 4 Kaplan–Meier overall relapse-free survival duration curve from
diagnosis of metastatic GCT for patients with HIV infection and matched
controls.
Table 4 Characteristics and outcome of patients with stage I GCT
treated with orchidectomy surveillance
HIV +ve HIV –ve
Number 16 48
Median age (range) 33.5 years (27–64 years) 33.5 years (25–64 years)
Median follow-up (range) 3.0 years (1–13 years) 3.8 years (0.1–14.6 years)
Relapses of GCT 4 (25%) 12 (25%)
GCT-related deaths 1 (6%) 1 (1%)
Other deaths (including HIV)* 3 (20% ) 0
This table does not include the five HIV-positive and 15 HIV-negative patients with
stage I disease that received adjuvant treatment. (GCT¼germ cell tumour).
*P40.05.
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Figure 5 Kaplan–Meier relapse-free survival duration curve from
diagnosis of stage I GCT for patients with HIV infection and matched
controls managed by orchidectomy and surveillance.
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Initial studies suggested that patients with HIV-related cancers
(Kaposi’s sarcoma, NHL and cervical cancer) had a worse outcome
compared to HIV-negative controls for three reasons. Firstly, the
HIV itself caused much of the mortality often due opportunistic
infections such as Pneumocystis carinii pneumonia (Bernardi et al,
1995). Secondly, it was speculated that patients with HIV infection
tolerated chemotherapy less well resulting in dose reductions that
entailed lower response rates (Wilson et al, 1992; Hentrich et al,
1996). The third possible reason for the decreased survival was due
to more aggressive tumours in this group or intrinsic chemother-
apy resistance in patients with HIV (Tessler and Catanese, 1987;
Sridhar et al, 1992; Vyzula and Remick, 1996).
Since the introduction of HAART, HIV-related mortality has
decreases and the outcome of patients with Kaposi’s sarcoma and
lymphomas have improved (Tam et al, 2002). We have also shown
that the survival of HIV-positive patients with lung cancer is not
significantly different to controls (Powles et al, 2003b). This
improved survival is thought to be due to not only decreased HIV
related mortality but also better tolerance of chemotherapy
(Sparano et al, 1998; Esdaile et al, 2002). However, for patients
with AIDS-related lymphoma, the problem of intrinsic chemother-
apy resistance persists (Little et al, 2000). One of the mechanisms
of increased intrinsic chemoresistance relates to over activity of
the p-glycoprotein efflux pump, which is associated with MDR-1
over expression, and occurs three times more frequently in AIDS-
related lymphoma than in lymphomas in the immunocompetent
population (Tulpule et al, 2002).
We demonstrate here for the first time that HIV-positive
patients with metastatic GCT have a similar disease-free survival
compared with HIV-negative controls. Our patients, with the
exception of one man who declined chemotherapy, were treated
with curative intent. These findings imply that unlike AIDS-related
lymphomas, HIV-related GCT is not an intrinsically chemoresis-
tant tumour.
Treatment toxicity in the HIV-positive and -negative cohorts
was not directly compared; however, there were no treatment-
related deaths in either group. This and other studies have
suggested that the HIV-positive group do not have excess toxicity
compared to historical HIV-negative controls (Williams et al, 1987;
Timmerman et al, 1995; Hentrich et al, 1996). The detrimental
effect of chemotherapy on immune parameters has been described
previously in this group, overall it is associated with a 30% fall in
the CD4 cell count (Powles et al, 2003a).
HIV-negative patients with GCT localised to the testis
are initially treated with orchidectomy. Further management of
these patients is controversial. Retroperitoneal lymph node
dissection, adjuvant chemotherapy and adjuvant radiotherapy
are all established treatment options. However, these patients
may be managed with surveillance alone, and despite a relapse
rate of approximately 30%, their overall survival is the same as
patients who received adjuvant treatment (Francis et al, 2000). To
date, the recommended treatment for stage I HIV-related GCT has
been orchidectomy and radiotherapy or retroperitoneal lymph
node dissection (Hentrich et al, 1996). This is in part due to a
fear that these patients may be at a higher risk of relapse and
that metastatic disease may be associated with a worse outcome
compared to HIV negative controls (Tessler and Catanese,
1987; Wilson et al, 1992). The data presented here show
that orchidectomy and surveillance and Catanese, do not result
in an increased relapse rate in these patients compared to the
HIV-negative population, and that this is a safe management
policy without the potentially immunosuppressive adjuvant
therapy. This is of particular importance in the HIV population
as they are more likely to succumb to HIV infection than recurrent
GCT. Patients on a surveillance programme must be competent
and fully compliant with the protocol to ensure the safety of this
regimen. Reports suggest intravenous drug abusers comply poorly
with treatment and are often lost to follow-up (Bernardi et al,
1995). It is therefore reasonable to encourage these patients to have
some form of adjuvant treatment in order to reduce the risk of
relapse.
The overall survival of patients with HIV-related GCT was worse
than HIV-negative controls in the pre-HAART era. The poor
outcome in this cohort was due to HIV-related disease, which was
responsible for seven of the nine deaths during this period. Since
the introduction of HAART fewer of these patients have died. This
is due to a decrease in HIV-associated complication rather than
improved GCT survival, with no HIV-related deaths in the post-
HAART era.
Previous studies have suggested ‘tailor made’ treatment for
patients with HIV related GCT in order to avoid potential
interactions and side effects associated with HIV and its treatment
(Wilson et al, 1992; Hentrich et al, 1996) However, this and other
studies suggest that patients tolerate standard treatment remark-
able well, and should be treated in an similar manner to HIV
negatives (Bernardi et al, 1995; Timmerman et al, 1995). To date,
no treatment-related deaths have been reported for an HIV-related
GCT patient. Cytotoxicity chemotherapy and radiotherapy have a
suppressive effect on immune parameters. Despite this, none of the
patients developed opportunistic infections in this or the other
large published series (Bernardi et al, 1995). This emphasises the
need for oncologists to work in conjunction with HIV physicians
with regard to commencing HAART and prophylaxis against
opportunistic infections.
In conclusion, it appears that patients with HIV-related GCT
have identical response rates and tumour-free survival compared
to HIV-negative controls. However, they have a decreased overall
survival emphasising the need for outcome studies such as this to
acquire information with regard to this end point.
Before the introduction of HAART, HIV was responsible for
much of the mortality of this group that has now reduced.
Orchidectomy and surveillance is a safe alternative to other forms
of adjuvant treatment and is not associated with an increased risk
of relapse. Unlike other HIV-related malignancies, GCT are not
intrinsically chemoresistant and have a similar response rate and
disease-free survival compared to HIV-negative controls.
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